QRxPharma Limited (QRX) announced that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023. This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.
“This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma’s MoxDuo opioid products for the treatment of acute and chronic pain,” said Dr. John Holaday, Managing Director and Chief Executive Officer. “This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year.”
The newly issued patent is directed to a method of treatment of pain using MoxDuo’s composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023. Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.
QRxPharma Limited (QRX) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company’s product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. QrxPharma’s lead product candidate, immediate release MoxDuo, has a Prescription Drug User Fee Act (PDUFA) date of 25 June 2012 when the New Drug Application review by the US Food and Drug Administration (FDA) will be completed.